Bollard Group’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$6.97M Sell
115,000
-11,294
-9% -$658K 0.21% 53
2025
Q4
$6.81M Sell
126,294
-7,511
-6% -$361K 0.17% 52
2025
Q3
$6.04M Buy
133,805
+5,297
+4% +$247K 0.14% 59
2025
Q2
$5.95M Buy
128,508
+7,811
+6% +$383K 0.14% 58
2025
Q1
$7.36M Buy
120,697
+1,019
+0.9% +$59.4K 0.19% 41
2024
Q4
$6.77M Sell
119,678
-935
-0.8% -$52.2K 0.19% 44
2024
Q3
$6.24M Sell
120,613
-14,689
-11% -$689K 0.17% 50
2024
Q2
$5.62M Buy
135,302
+6,506
+5% +$291K 0.16% 49
2024
Q1
$6.99M Buy
128,796
+2,819
+2% +$144K 0.21% 42
2023
Q4
$6.46M Sell
125,977
-31,232
-20% -$1.64M 0.22% 43
2023
Q3
$9.12M Sell
157,209
-11,063
-7% -$678K 0.34% 37
2023
Q2
$10.8M Buy
168,272
+1,184
+0.7% +$79.4K 0.37% 39
2023
Q1
$11.6M Buy
167,088
+887
+0.5% +$62.6K 0.42% 35
2022
Q4
$12M Sell
166,201
-7,884
-5% -$594K 0.46% 34
2022
Q3
$12.4M Buy
174,085
+874
+0.5% +$63.4K 0.52% 33
2022
Q2
$13.3M Buy
173,211
+1,093
+0.6% +$83.2K 0.54% 33
2022
Q1
$12.6M Buy
172,118
+11,747
+7% +$789K 0.4% 41
2021
Q4
$10M Buy
160,371
+1,174
+0.7% +$68.9K 0.32% 50
2021
Q3
$9.42M Buy
159,197
+8,246
+5% +$543K 0.31% 53
2021
Q2
$10.1M Buy
150,951
+11,117
+8% +$725K 0.32% 46
2021
Q1
$8.83M Buy
139,834
+820
+0.6% +$51K 0.31% 44
2020
Q4
$8.62M Buy
139,014
+783
+0.6% +$48.1K 0.32% 44
2020
Q3
$8.33M Buy
138,231
+481
+0.3% +$28.9K 0.3% 47
2020
Q2
$8.1M Buy
137,750
+2
+0% +$120 0.32% 48
2020
Q1
$7.68M Buy
137,748
+576
+0.4% +$35.2K 0.34% 45
2019
Q4
$8.8M Buy
137,172
+565
+0.4% +$32.4K 0.29% 52
2019
Q3
$6.93M Sell
136,607
-54,230
-28% -$2.55M 0.24% 61
2019
Q2
$8.65M Sell
190,837
-57,508
-23% -$2.68M 0.3% 48
2019
Q1
$11.8M Buy
248,345
+27,745
+13% +$1.38M 0.45% 29
2018
Q4
$11.5M Buy
220,600
+10,858
+5% +$583K 0.51% 25
2018
Q3
$13M Buy
209,742
+8,828
+4% +$524K 0.52% 22
2018
Q2
$11.1M Buy
200,914
+3,789
+2% +$205K 0.51% 25
2018
Q1
$12.5M Buy
197,125
+6,771
+4% +$436K 0.62% 21
2017
Q4
$11.7M Sell
190,354
-1,281
-0.7% -$80.1K 0.56% 23
2017
Q3
$12.2M Buy
191,635
+3,634
+2% +$212K 0.64% 22
2017
Q2
$10.5M Buy
188,001
+1,528
+0.8% +$83.1K 0.57% 28
2017
Q1
$10.1M Buy
186,473
+13,425
+8% +$736K 0.58% 26
2016
Q4
$10.1M Buy
173,048
+1,708
+1% +$93.4K 0.66% 21
2016
Q3
$9.24M Buy
171,340
+677
+0.4% +$43.5K 0.59% 21
2016
Q2
$12.6M Buy
170,663
+715
+0.4% +$50.5K 0.86% 12
2016
Q1
$10.9M Buy
169,948
+825
+0.5% +$52K 0.87% 16
2015
Q4
$11.6M Buy
169,123
+741
+0.4% +$49K 0.96% 15
2015
Q3
$9.97M Buy
168,382
+918
+0.5% +$58.2K 0.82% 19
2015
Q2
$11.1M Buy
167,464
+934
+0.6% +$61.6K 0.84% 18
2015
Q1
$10.7M Buy
166,530
+4,590
+3% +$287K 0.8% 18
2014
Q4
$9.56M Buy
161,940
+7,056
+5% +$398K 0.84% 18
2014
Q3
$7.93M Buy
154,884
+8,415
+6% +$420K 0.75% 22
2014
Q2
$7.11M Buy
146,469
+2,489
+2% +$123K 0.69% 24
2014
Q1
$7.48M Buy
143,980
+355
+0.2% +$18.9K 0.76% 21
2013
Q4
$7.63M Buy
143,625
+3,538
+3% +$180K 0.84% 19
2013
Q3
$6.48M Buy
140,087
+25,676
+22% +$1.13M 0.76% 22
2013
Q2
$5.11M Buy
+114,411
New +$4.97M 0.98% 27

Other funds holding BMY

Bollard Group's BMY Position: Q1 2026 in Review

Bollard Group reduced its Bristol-Myers Squibb (BMY) stake by 8.9% in Q1 2026, selling an estimated $658K and leaving 115,000 shares worth $6.97M. The position accounts for 0.21% of the portfolio, ranked #53.

Bollard Group first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $13.3M in Q2 2022. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Bollard Group held 115,000 shares of Bristol-Myers Squibb worth $6.97M as of Q1 2026.
  • Bollard Group sold 11,294 Bristol-Myers Squibb shares in Q1 2026, an estimated $658K.
  • Bristol-Myers Squibb made up 0.21% of Bollard Group's portfolio in Q1 2026, its #53 holding.
  • Bollard Group first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
  • Bollard Group's Bristol-Myers Squibb position peaked at $13.3M in Q2 2022.
  • 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Bollard Group's 13F filing for Q1 2026, filed 14 May 2026.